{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:01:33Z","timestamp":1770822093620,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T00:00:00Z","timestamp":1107820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fondaparinux (Arixtra<jats:sup>\u00ae<\/jats:sup>) is the first selective factor Xa inhibitor approved for use in thromboprophylaxis after orthopaedic surgery. New recently completed trials have also demonstrated the potential of fondaparinux in the prevention of venous thromboembolism (VTE) in other surgical and medical settings and in the treatment of established VTE. In the randomized double\u2010blind PEGASUS study in high\u2010risk abdominal surgery patients, fondaparinux reduced the incidence of VTE from 6\u00b71% with dalteparin to 4\u00b76% (odds ratio reduction\u00a0=\u00a025\u00b78%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b714), without increasing the bleeding risk. In the randomized double\u2010blind ARTEMIS trial in acutely ill medical patients, fondaparinux reduced the incidence of VTE from 10\u00b75% with placebo to 5\u00b76% (odds ratio reduction\u00a0=\u00a049\u00b75%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7029), without increasing the bleeding risk; there was no pulmonary embolism in the fondaparinux group compared with five, all fatal, in the placebo group (<jats:italic>P\u00a0=<\/jats:italic>\u00a00\u00b7029). In the two MATISSE trials, both the efficacy and safety of once daily fondaparinux were at least as good as enoxaparin in the treatment of deep\u2010vein thrombosis (MATISSE\u2013DVT) and unfractionated heparin in the treatment of pulmonary embolism (MATISSE\u2010PE). In patients with coronary artery disease, promising results were obtained in phase II trials and large phase III trials are ongoing. In conclusion, fondaparinux may further improve and simplify the prevention and treatment of thrombosis in a large range of medical and surgical settings.<\/jats:p>","DOI":"10.1111\/j.0960-135x.2005.01454.x","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T14:11:23Z","timestamp":1107871883000},"page":"27-32","source":"Crossref","is-referenced-by-count":22,"title":["Fondaparinux: an update on new study results"],"prefix":"10.1111","volume":"35","author":[{"given":"R. M.","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,8]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103013440901"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011099"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011100"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08652-X"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08648-8"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.16.1833"},{"key":"e_1_2_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.11.1337"},{"key":"e_1_2_3_9_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.132S"},{"key":"e_1_2_3_10_2","first-page":"663","article-title":"Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran","volume":"161","author":"Wiig JN","year":"1995","journal-title":"Eur J Surg"},{"key":"e_1_2_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800840817"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200103000-00020"},{"key":"e_1_2_3_13_2","unstructured":"AgnelliG BergqvistD CohenA GallusAS GentM.A randomized double\u2010blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra\u00ae) and preoperative dalteparin in the prevention of venous thromboembolism after high\u2010risk abdominal surgery: the PEGASUS Study.Blood2003:102: abstract 40."},{"key":"e_1_2_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411103"},{"key":"e_1_2_3_15_2","unstructured":"CohenAT DavidsonBL GallusAS LassenMR TomkowskiW TurpieAGGet al.Fondaparinux for the prevention of venous thromboembolism in acutely ill medical patients.Blood2003:102: abstract 42."},{"key":"e_1_2_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.22.2726"},{"key":"e_1_2_3_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-11-200406010-00007"},{"key":"e_1_2_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035451"},{"key":"e_1_2_3_19_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0037-1614445","article-title":"Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty","volume":"81","author":"Vuillemenot A","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_3_20_2","first-page":"1b","article-title":"The PENTUA Study: Double\u2010blind dose\u2010ranging study of fondaparinux (pentasaccharide) in unstable angina","volume":"104","author":"Simmoons M","year":"2001","journal-title":"Circulation"},{"key":"e_1_2_3_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2777"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0960-135X.2005.01454.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0960-135X.2005.01454.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T02:44:13Z","timestamp":1695782653000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0960-135X.2005.01454.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,8]]},"references-count":20,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.0960-135X.2005.01454.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0960-135x.2005.01454.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,8]]}}}